Astellas to Launch Xospata (gilteritinib) for R/R Acute Myeloid Leukemia (AML) with FLT3 Mutation, in the US

Shots:

• On 28 Nov, 2018 Xospata (gilteritinib) received FDA approval as a PO monothx, indicated for r/r FLT3 mutation-positive (FLT3mut+) AML
• Xospata is accompanied by Xospata Support Solutions offering access and reimbursement support to patients and also provides information regarding patient healthcare coverage options and financial assistance programs
• Xospata 40 mg (gilteritinib) is a FLT3 inhibitor, approved by Japan Ministry of Health, Labor and Welfare (MHLW) for r/r AML with FLT3 mutations and is being evaluated in P-III for multiple FLT3 mutation-positive AML

Click here to read full press release/ article | Ref: Astellas | Image: Pharma Field